QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)
QQQ   444.02 (-0.36%)
AAPL   175.10 (-2.54%)
MSFT   414.92 (-0.14%)
META   498.19 (-0.82%)
GOOGL   133.35 (-2.76%)
AMZN   177.58 (-0.36%)
TSLA   188.14 (-7.16%)
NVDA   852.37 (+3.60%)
NIO   5.35 (-7.44%)
AMD   205.36 (+1.34%)
BABA   72.00 (-3.51%)
T   16.80 (-1.06%)
F   12.74 (+2.33%)
MU   95.77 (+0.65%)
CGC   3.02 (-5.92%)
GE   161.04 (+1.51%)
DIS   113.69 (+1.55%)
AMC   4.32 (-0.92%)
PFE   25.89 (-2.63%)
PYPL   59.98 (-0.93%)
XOM   104.36 (-1.40%)

Natera (NTRA) Stock Price, News & Analysis

$90.21
+0.80 (+0.89%)
(As of 03/4/2024 ET)
Today's Range
$87.72
$90.90
50-Day Range
$59.21
$89.41
52-Week Range
$36.90
$90.90
Volume
1.73 million shs
Average Volume
1.51 million shs
Market Capitalization
$10.89 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$75.50

Natera MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
16.3% Downside
$75.50 Price Target
Short Interest
Bearish
6.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.41mentions of Natera in the last 14 days
Based on 37 Articles This Week
Insider Trading
Selling Shares
$55.70 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.52) to ($1.09) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.46 out of 5 stars

Medical Sector

753rd out of 948 stocks

Medical Laboratories Industry

18th out of 20 stocks


NTRA stock logo

About Natera Stock (NASDAQ:NTRA)

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company's products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

NTRA Stock Price History

NTRA Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Natera Full Year 2023 Earnings: Beats Expectations
Natera (NASDAQ:NTRA) Price Target Raised to $100.00
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Decoding Natera Inc (NTRA): A Strategic SWOT Insight
Natera (NASDAQ:NTRA) Shares Gap Up on Analyst Upgrade
Natera to Participate in March Investor Conferences
Recap: Natera Q4 Earnings
Earnings Preview For Natera
Natera (NTRA) Management Increased Full Year Guidance
Natera (NASDAQ:NTRA) Cut to Sell at StockNews.com
See More Headlines
Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
3/04/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:NTRA
Fax
N/A
Employees
3,293
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$75.50
High Stock Price Target
$100.00
Low Stock Price Target
$48.00
Potential Upside/Downside
-15.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
13 Analysts

Profitability

Net Income
$-434,800,000.00
Pretax Margin
-40.14%

Debt

Sales & Book Value

Annual Sales
$1.08 billion
Book Value
$6.37 per share

Miscellaneous

Free Float
109,383,000
Market Cap
$10.73 billion
Optionable
Optionable
Beta
1.39
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report














NTRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Natera stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NTRA shares.
View NTRA analyst ratings
or view top-rated stocks.

What is Natera's stock price target for 2024?

13 equities research analysts have issued twelve-month target prices for Natera's stock. Their NTRA share price targets range from $48.00 to $100.00. On average, they predict the company's stock price to reach $75.50 in the next twelve months. This suggests that the stock has a possible downside of 16.3%.
View analysts price targets for NTRA
or view top-rated stocks among Wall Street analysts.

How have NTRA shares performed in 2024?

Natera's stock was trading at $62.64 at the beginning of 2024. Since then, NTRA stock has increased by 44.0% and is now trading at $90.21.
View the best growth stocks for 2024 here
.

When is Natera's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our NTRA earnings forecast
.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) issued its quarterly earnings results on Wednesday, November, 8th. The medical research company reported ($0.95) earnings per share for the quarter, topping analysts' consensus estimates of ($0.96) by $0.01. The medical research company had revenue of $268.30 million for the quarter, compared to analyst estimates of $259.27 million. Natera had a negative trailing twelve-month return on equity of 62.19% and a negative net margin of 40.16%. The company's quarterly revenue was up 27.4% on a year-over-year basis. During the same quarter last year, the company posted ($1.25) earnings per share.

What guidance has Natera issued on next quarter's earnings?

Natera issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion.

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Natera own?
When did Natera IPO?

(NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Who are Natera's major shareholders?

Natera's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (9.13%), RTW Investments LP (2.16%), Kynam Capital Management LP (2.00%), Principal Financial Group Inc. (1.42%), Norges Bank (1.12%) and Avidity Partners Management LP (0.92%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, John Fesko, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends
.

How do I buy shares of Natera?

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NTRA) was last updated on 3/4/2024 by MarketBeat.com Staff